

Genomtec received positive evaluation of Grant in Oncology Diagnostics from the Polish Agency for Enterprise Development (PARP) and the European Funds for a Modern Economy program

Genomtec S.A., a leading company in the molecular diagnostics industry based in Wrocław, Poland (Warsaw Stock Exchange: GMT ticker), announced that on October 19, 2023, the Polish Agency for Enterprise Development (PARP) released the results of the evaluation of the Grant application submitted by the Company as part of the European Funds for a Modern Economy program.

The Genomtec project, titled "Development of technology and an automatic system for mutation detection in clinical oncology based on lab-on-a-chip solutions and isothermal nucleic acid amplification techniques," is among 198 applications positively evaluated by PARP in the SMART FENG.01.01-IP.02-001/23/2023 action within the European Funds for a Modern Economy program.

The recommended funding amount for the project is approximately PLN 21.6 million, with a total project budget of around PLN 40 million. If the grant funding is secured, the project will be implemented from January 2024 to June 2027.

"We are very pleased that our project has been positively evaluated and recommended for funding by PARP. This success, confirmed by independent experts, once again validates the value of our technology and the strength and experience of the team we have gathered over the past years. This support will provide us with financial stability as we continue to develop our diagnostic platform based on isothermal nucleic acid amplification techniques for oncology diagnostics. Innovative methods and intensive laboratory work has allowed us to submit a patent application in September of this year to protect this invention in the field of oncology. This also expands the applications of our proprietary SNAAT method beyond infectious disease diagnostics. It opens the door for discussions with a significantly broader spectrum of potential partners interested in acquiring our company." says Miron Tokarski, CEO of Genomtec S.A.

The purpose of Grant requested for funding by PARP, is the development of technology and an automatic system for mutation detection in the field of clinical oncology based on lab-on-a-chip solutions and isothermal nucleic acid amplification techniques. The project comprises three modules: Research and Development (R&D), Digitization, and Internationalization.

As part of the R&D module, laboratory work will be conducted on the technology for mutation detection in oncological diagnostics using microfluidic cards to enable diagnostics and the application of molecularly targeted therapy. Under the Digitization module, investments will be made in software solutions streamlining development and design of molecular IVD systems. Within the Internationalization module, participation in various international trade events and the protection of Genomtec S.A.'s intellectual property have been planned.

At the same time, Genomtec is actively working on its most advanced project related to respiratory infectious disease diagnostics - the Genomtec ID platform. The company is collaborating with

experienced partners to optimize the costs of future platform production and operation, as well as scalability in production, including the reaction card and its components, as well as the analyzer. According to the plan, clinical trials will be resumed in France and Poland for comparative studies of the Genomtec ID platform and the 5-plex panel for respiratory tract infection detection. This is aimed at achieving their registration in accordance with IVDR regulations before the expiration of the current approval in May 2025.

About Genomtec

Genomtec is a MedTech company specializing in the development of advanced technologies in the field of genetic diagnostics. The company's flagship project is the Genomtec ID mobile diagnostic system. The system allows for fast and precise molecular analysis outside the laboratory environment without the need to involve qualified laboratory personnel. The solution uses microfluidic technology and proprietary patented SNAAT isothermal technology. The Genomtec technology is protected by 10 patents in Europe, the USA and Japan, and over 35 patent pending applications on global markets.

The company has EU CE-IVD certification for the Genomtec ID RP5-PLEX diagnostic panel, which simultaneously detects the presence of the most common respiratory tract infections.

The company's registered office is located in Wrocław. Genomtec also has a branch in the UK, where part of the international research and engineering team is located.

More information is available on the shelf page: www.genomtec.com

Media Contact:

Michał Wierzchowski

Tel.: +48 531 613 067

michal.wierzchowski@ccgroup.pl

Contact for investors:

Agata Dzieciotowska

Tel.: +48 606 205 119

agata.dzieciolowska@ccgroup.pl

Małgorzata Młynarska

Tel.: +48 697 613 709

malgorzata.mlynarska@ccgroup.pl